India Globalization Cap.Inc. Registered Shares DL -,01

WKN A1T87A ISIN US45408X3089

Quote/Chart

  • Bid

    0.412

    1,100 Units

  • Ask

    0.452

    2,500 Units

  • Change compared with previous day (price)

    +0.01 / +2.50 %

  • Spread (Act/ Rel)

    0.040 / 9.709 %

  • Today's high (Price)

    0.41

  • Today's low (Price)

    0.41

Facts & figures

Price data

Trade platform Börse Stuttgart (XSTU)  
Last price 0.41 G 0 Units
Price determination time 07/23/2024 / 10:45:27 AM
Daily volume (units) 0
Daily high / low 0.41 0.41
Prev. day's price 0.4 (22.07.)
Change day before +0.01 2.50 %
52 week high / low 0.665 (05/04) 0.216 (12/01)

Key Figures (in EUR)

2023 2022 2021
Earnings per share -0.20 -0.21 -0.26
Dividends per share 0.00 0.00 0.00
Dividend Yield in % 0.00% 0.00% 0.00%
Dividend growth in % - - -
Price - Earnings ratio - - -
Price - Book ratio 3.64 1.21 2.03
Price - Sales ratio 17.50 19.59 119.49
Price - Cash Flow Ratio - - -

Master Data

WKN
A1T87A
ISIN
US45408X3089
Symbol
-
Exchange segment
Freiverkehr
Type of financial instrument
Equity
Denomination
India Globalization Capital
Index membership
-
Trading segment
-
Trading hours
08:00:00 - 22:00:00
Trading currency
Euro
Nominal currency
-
Settlement currency
Euro
Sector and industry
Chemical/Pharmaceutical/Health, Health Services
Number of shares
-
Market capitalisation
-

Performance overview

1W 1M 3M 6M 1Y 3Y 5Y YTD
Performance 6.95% 16.28% -11.50% 58.73% 31.58% -83.28% -66.69% 52.67%
High 0.42 0.43 0.55 0.66 0.66 2.05 3.63 0.66
Low 0.36 0.33 0.33 0.22 0.22 0.22 0.22 0.22

Company profile

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.